TriangleNCT03389802 · OUTCOME
Overall Survival for Stratum 2 (DIPG) Patients
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percent probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 1 year
What was measured
Overall survival was defined as the time interval from treatment initiation to death from any cause or to date of last follow-up for survivors. Survival was estimated using the method of Kaplan and Meier. The 1-year estimate of survival is reported with a 95% confidence interval; estimates are reported by dose level. Stratum 2 patients were those with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Analysis population: Newly diagnosed DIPG patients who were enrolled on Stratum 2 and received at least one dose of APX005M were included in this analysis.
Groups in this outcome
Stratum 2, Dose Level 2
Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.
Stratum 2, Dose Level 3
Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.
| Group | Source count |
|---|---|
| Stratum 2, Dose Level 2 | 6 |
| Stratum 2, Dose Level 3 | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Stratum 2, Dose Level 2 | 40.0 | Not reported | 4.9 | 75.1 | Not reported |
| Stratum 2, Dose Level 3 | 25.0 | Not reported | 0.0 | 55.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.9
- upper Limit
- 75.1
- value
- 40.0
- group Id
- OG001
- lower Limit
- 0.0
- upper Limit
- 55.0
- value
- 25.0
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 5
- units
- Participants
- description
- Overall survival was defined as the time interval from treatment initiation to death from any cause or to date of last follow-up for survivors. Survival was estimated using the method of Kaplan and Meier. The 1-year estimate of survival is reported with a 95% confidence interval; estimates are reported by dose level. Stratum 2 patients were those with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.
- id
- OG000
- title
- Stratum 2, Dose Level 2
- description
- Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.
- id
- OG001
- title
- Stratum 2, Dose Level 3
- param Type
- NUMBER
- population Description
- Newly diagnosed DIPG patients who were enrolled on Stratum 2 and received at least one dose of APX005M were included in this analysis.
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Overall Survival for Stratum 2 (DIPG) Patients
- type
- SECONDARY
- unit Of Measure
- Percent probability
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice